Merck’s big plans for its R&D efforts on both coasts mean it will close an operation in Pennsylvania, costing some jobs there and in New Jersey while adding jobs elsewhere.
The Kenilworth, NJ-based drugmaker today confirmed a report by the In The Pipeline blog about its plans. In an email, the company said Merck Research Laboratories intends to boost its investment in ”exploratory biology,” specifically in Cambridge, MA, and the San Francisco Bay area.
“Unfortunately, these changes will result in workforce reductions at our Kenilworth and Rahway, N.J. sites and our North Wales, Pa. screening facility as we shift resources and personnel,” the company said.
Merck isn’t providing any specific numbers on what the move will mean for jobs at each operation, but it anticipates that it’ll affect less than 10% of discovery, preclinical and early development personnel, including through both separations and employee moves.
The expansion includes new labs in Cambridge that it expects to open late this year. There will also be an interim facility in South San Francisco opening late this year, with about 100 scientists expected to be recruited there. Merck’s looking for a long-term site in that area.
By Eric Palmer
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
